290 related articles for article (PubMed ID: 12610780)
1. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
[TBL] [Abstract][Full Text] [Related]
2. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
[TBL] [Abstract][Full Text] [Related]
3. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
[TBL] [Abstract][Full Text] [Related]
4. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
5. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
[TBL] [Abstract][Full Text] [Related]
6. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.
Sodha N; Bullock S; Taylor R; Mitchell G; Guertl-Lackner B; Williams RD; Bevan S; Bishop K; McGuire S; Houlston RS; Eeles RA
Br J Cancer; 2002 Dec; 87(12):1445-8. PubMed ID: 12454775
[TBL] [Abstract][Full Text] [Related]
7. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
[TBL] [Abstract][Full Text] [Related]
8. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
[TBL] [Abstract][Full Text] [Related]
9. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
[TBL] [Abstract][Full Text] [Related]
10. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
11. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
12. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
Rajkumar T; Soumittra N; Nancy NK; Swaminathan R; Sridevi V; Shanta V
Asian Pac J Cancer Prev; 2003; 4(3):203-8. PubMed ID: 14507240
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
14. CHEK2 variant I157T may be associated with increased breast cancer risk.
Kilpivaara O; Vahteristo P; Falck J; Syrjäkoski K; Eerola H; Easton D; Bartkova J; Lukas J; Heikkilä P; Aittomäki K; Holli K; Blomqvist C; Kallioniemi OP; Bartek J; Nevanlinna H
Int J Cancer; 2004 Sep; 111(4):543-7. PubMed ID: 15239132
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
16. Frequency of CHEK2*1100delC in New York breast cancer cases and controls.
Offit K; Pierce H; Kirchhoff T; Kolachana P; Rapaport B; Gregersen P; Johnson S; Yossepowitch O; Huang H; Satagopan J; Robson M; Scheuer L; Nafa K; Ellis N
BMC Med Genet; 2003 Jan; 4():1. PubMed ID: 12529183
[TBL] [Abstract][Full Text] [Related]
17. Limited relevance of the CHEK2 gene in hereditary breast cancer.
Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
[TBL] [Abstract][Full Text] [Related]
18. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
[TBL] [Abstract][Full Text] [Related]
19. CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
[TBL] [Abstract][Full Text] [Related]
20. CHEK2 1100delC is not a risk factor for male breast cancer population.
Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
